Asthma Treatment Market To Expand to US$ 38.3 Billion By 2033

Introduction

Global Asthma Treatment Market size is expected to be worth around US$ 38.3 Billion by 2033, from US$ 26.1 Billion in 2023, growing at a CAGR of 3.9% during the forecast period from 2024 to 2033. In 2023, North America held over 51.2% market share, reaching a revenue total of US$ 13.3 Billion.

This growth is driven by several factors, including the rising prevalence of asthma linked to poor air quality and environmental issues, increased public awareness, and advancements in treatment options. Notably, monoclonal antibodies (mAbs) targeting specific cytokines and immunoglobulin E (IgE) have gained traction in managing chronic asthma cases that are unresponsive to traditional therapies.

Inhalers dominate the asthma treatment market due to their reliability, portability, and affordability. Innovations such as triple therapy inhalers for asthma and Chronic Obstructive Pulmonary Disease (COPD) have further boosted their adoption. Inhaled medications remain the preferred route of administration, offering targeted delivery with minimal side effects.

The market is also experiencing a shift toward personalized medicine. Combination therapies and biologics are increasingly tailored to individual patient needs, enhancing disease management and emphasizing patient-centric approaches. This trend highlights the industry’s focus on effective and customized treatment solutions.

Despite these advancements, affordability and accessibility challenges persist. The high cost of medications, including biologics, limits access for many patients, potentially affecting adherence and treatment outcomes. However, initiatives to improve affordability, such as generic alternatives and patient assistance programs, aim to address these barriers.

Recent developments include AstraZeneca’s Tezspire, a severe asthma therapy approved in the EU with a new self-administration pen injector. This is the first EU biologic therapy for severe asthma without phenotype or biomarker restrictions, potentially benefiting 2.5 million patients worldwide. Tezspire demonstrated a 92% success rate in self-administration during phase studies and is projected to become a $1 billion product, achieving $91 million in U.S. sales in the first nine months of 2022.

Teva Pharmaceuticals has also advanced its innovation strategy through its “Pivot to Growth” initiative. This includes a focus on high-value generics and innovative treatments, such as an anti-TL1A currently in phase 2 trials for asthma, which addresses underserved markets. The introduction of digital inhalers, such as AirDuo Digihaler and ArmonAir Digihaler, integrates digital technology into asthma management, providing enhanced insights for patients and healthcare providers.

In 2023, Teva reported a 10% increase in gross profit to USD 7,645 million, despite economic challenges. Research and development expenditures rose by 14% to USD 953 million, reflecting its commitment to an innovative pipeline. Additionally, a strategic partnership with Alvotech aims to expand its biosimilar portfolio, demonstrating Teva’s dedication to broadening its market presence.

Key Takeaways

• In 2023, the long-term control medication sector led the asthma treatment market significantly, securing 65.4% of the total market share.
• The inhalation route of administration emerged as the foremost method, holding a commanding share of 53.8% in the global asthma treatment market.
• Hospital pharmacies are the primary distribution channel for asthma treatments, maintaining a dominant market share of 59.4%.
• The increasing incidence of respiratory diseases, including asthma, and swift product approvals have significantly propelled the market forward in recent years.
• With a substantial revenue share of 51.2%, North America stands as the leading region in the global asthma treatment market for the year 2023.

Asthma Treatment Statistics

• Tezspire Pricing: In the United States, Tezspire is priced at approximately $47,000 annually.
• Teva Pharmaceuticals Revenue Projections: AUSTEDO® and AJOVY® are projected to contribute over $2.5 billion annually to Teva’s revenue by 2027.
• UZEDY™ Therapy: Targets over 600,000 schizophrenia patients with a unique therapeutic profile.
• Medication Adherence: Around 50% of asthma patients do not adhere to prescribed medication regimens, leading to poor symptom control and increased exacerbation risks.
• Effectiveness of Inhaled Corticosteroids (ICS): ICS reduce asthma exacerbation risks by 50-60% and improve lung function by 15-20%.
• Impact of Biologic Therapies: Treatments like omalizumab and mepolizumab reduce exacerbations by 50% in severe asthma cases unresponsive to standard therapies.
• Role of Immunotherapy: Sublingual immunotherapy (SLIT) reduces asthma symptoms by up to 30% and rescue medication usage by 40%.
• Emergency Department Visits: Uncontrolled asthma leads to approximately 2 million emergency visits globally every year, significantly burdening healthcare systems.
• Global Economic Burden: The annual economic cost of asthma exceeds $80 billion, driven by medical expenses, productivity losses, and absenteeism.
• Pediatric Asthma Management: Early diagnosis and proper management reduce hospital admissions by 50% and improve the quality of life for children and families.
• Non-Pharmacological Interventions: Smoking cessation programs and environmental control measures reduce asthma exacerbations by 30-50%.
• Patient Education Benefits: Asthma self-management education programs result in a 50% reduction in hospital admissions and emergency visits, enhancing disease control.
• Global Prevalence: In 2019, asthma affected 262 million people and caused 455,000 deaths, with most fatalities occurring in lowand lower-middle-income countries.
• Asthma in India: Among India’s 1.36 billion population, approximately 35 million suffer from asthma. Underdiagnosis and inadequate treatment remain major challenges.
• Asthma in Australia:
  • Health Expenditure: In 2020–21, Australia spent approximately $851.7 million on asthma treatment and management, representing 0.6% of total health expenditure.
  • Prevalence: Nearly 2.8 million Australians (10.8%) had asthma in 2022.
  • Action Plans: About 32.1% of individuals with asthma had a written action plan.
  • Medication Use: Approximately 33.9% used asthma medication daily.

Emerging Trends in Asthma Management

• AI and Data Analytics in Patient Monitoring: Artificial Intelligence (AI) and data analytics are transforming chronic condition management, including asthma. Technologies enabling real-time health monitoring and predictive analytics are advancing rapidly, facilitating personalized treatment plans and proactive healthcare management. Innovations like Philips HealthSuite and the AI-powered OXOS Micro C handheld x-ray device enhance diagnostic accuracy, patient monitoring, and early intervention, contributing to improved healthcare delivery and patient outcomes.
• Wearables and Telemedicine: The integration of wearables and telemedicine is revolutionizing patient care. Devices like the Apple Watch with FDA-cleared ECG functions demonstrate the potential for remote monitoring and engagement. AI-driven analytics, natural language processing, and machine learning enable personalized symptom triage and health plan development. The growth of telemedicine and mobile health applications highlights a shift toward more accessible, personalized, and efficient healthcare services.
• Robotics in Healthcare: Robotics, augmented by AI, is bringing innovative solutions to healthcare, including asthma management. While robotics is commonly used in surgery and rehabilitation, its potential in respiratory care includes automating inhaled medication delivery and developing advanced diagnostic tools. These innovations underscore robotics’ ability to refine complex medical procedures and support asthma patients.
• 3D Printing for Personalized Medical Devices: 3D printing is transforming the production of medical devices, including asthma management tools. Custom-fit devices, such as personalized inhalers and spacers, improve comfort and effectiveness for patients. This focus on personalization reflects a broader shift toward individualized healthcare solutions, enhancing adherence to treatment and improving outcomes.
• Digital Health Solutions: The proliferation of digital health solutions, such as mobile apps and online patient platforms, provides asthma patients with tools for effective condition management. Features like symptom tracking, medication reminders, and telehealth consultations empower patients to actively participate in their healthcare. These digital innovations improve self-management, reduce emergency care reliance, and align with broader trends in healthcare accessibility and patient engagement.

Use Cases in Asthma Management

• Daily Management and Preventative Care: Long-term control medicines, such as inhaled corticosteroids and biologic therapies, are essential for managing chronic asthma symptoms. These treatments reduce airway inflammation and prevent asthma attacks, improving the quality of life.
• Quick-Relief Medications for Acute Attacks: Quick-relief medicines, including short-acting beta2-agonists (SABAs) and oral corticosteroids, provide immediate relief during asthma attacks. These medications are vital for emergency use, and patients should carry a quick-relief inhaler at all times.
• Bronchial Thermoplasty for Severe Asthma: For severe asthma cases unresponsive to standard treatments, bronchial thermoplasty offers an alternative. The procedure uses heat to reduce airway muscle thickness and prevent narrowing. While effective, it carries risks, such as temporary symptom worsening or infections.
• Creating an Asthma Action Plan: A personalized asthma action plan, developed with a healthcare provider, is critical for effective management. The plan includes trigger avoidance strategies, medication schedules, steps to take during an attack, and emergency contacts, empowering patients to manage their condition proactively.
• Monitoring and Adjusting Treatment: Asthma control requires regular monitoring and treatment adjustments. Devices like peak flow meters and spirometers allow patients to measure lung function at home. Based on these results, healthcare providers can tailor treatment plans for optimal asthma control.
• Lifestyle and Environmental Modifications: Lifestyle and environmental changes significantly impact asthma management. Avoiding allergens, using air filters, and engaging in regular exercise help improve lung function. Proper inhaler use and adherence to treatment plans are also crucial for effective symptom control.

Key Players in the Asthma Treatment Market

• AstraZeneca: AstraZeneca has introduced innovative treatments such as Tezspire (tezepelumab-ekko) for severe asthma and Airsupra (albuterol/budesonide) for bronchoconstriction and exacerbation prevention. These approvals, based on rigorous clinical trials, highlight the company’s dedication to addressing complex asthma needs with advanced therapies.
• Teva Pharmaceutical Industries: Teva’s CINQAIR (reslizumab) targets severe asthma with an eosinophilic phenotype, offering a novel biologic option. Additionally, Teva’s Digihaler technology, the first smart inhaler system, demonstrates its commitment to integrating technology with asthma care for better outcomes.
• Sanofi-Aventis SA: Dupixent (dupilumab) is a breakthrough biologic for type 2 inflammation-related asthma. It reduces exacerbations, improves lung function, and decreases corticosteroid dependency, reinforcing Sanofi’s focus on innovative asthma solutions.
• Mundi-Pharma: Known for its advanced delivery systems, Mundi-Pharma’s collaboration with Vectura on VR2076 (inhaled triple therapy) simplifies asthma management. The K-Haler device enhances patient adherence by addressing common usage errors.
• GlaxoSmithKline (GSK): GSK’s acquisition of Aiolos Bio for $1.4 billion strengthens its respiratory biologics portfolio. Products like mepolizumab for severe eosinophilic asthma and ongoing research into GSK’294 exemplify GSK’s commitment to personalized asthma care.
• Merck & Co., Inc.: Merck’s DULERA (mometasone and formoterol) combines an inhaled corticosteroid with a long-acting beta2-agonist for persistent asthma. Proven to improve lung function, this product underscores Merck’s dedication to innovative asthma therapies.

Conclusion

In conclusion, the global asthma treatment market is witnessing significant growth, driven by increasing asthma prevalence, innovations in biologics and inhaler technologies, and a shift toward personalized treatment approaches. While inhalers continue to dominate, advancements like biologics and digital inhalers are enhancing treatment options.

Despite challenges in affordability and accessibility, initiatives to improve medication access are gaining traction. Key players, including AstraZeneca, Teva, and Sanofi, are driving innovation with new therapies and technologies, contributing to improved asthma management. The market is poised for continued expansion, reflecting ongoing progress in treatment efficacy and patient care.

Discuss your needs with our analyst

Please share your requirements with more details so our analyst can check if they can solve your problem(s)

Request a Sample Download PDF